HTG Molecular Diagnostics and Qiagen combine forces.

HTG Molecular Diagnostics and Qiagen announced a Commercialization and Distribution Agreement that will be foundational for both companies as they combine their respective technologies to enhance global development in the pharmaceutical industry. The 10 year agreement will “offer pharmaceutical companies global development, distribution and commercialization capabilities for companion diagnostic (CDx) assays based on HTG EdgeSeq, HTG’s novel RNA platform.”

Source: https://www.biospace.com/article/releases/htg-molecular-diagnostics-announces-new-commercialization-and-distribution-agreement-for-companion-diagnostics-with-qiagen/?s=90